Professor Chris Whitty, chief scientific adviser for the Department of Health and Social Care (DHSC), on the role of the NIHR and the promise of the government's second sector deal for the life sciences industry.
6th December 2018
Mark Toms, chief scientific officer at Novartis Pharmaceuticals UK, looks at how to address the challenges of recruiting for Alzheimer’s prevention studies.
6th December 2018
There are around 7,000 rare diseases for which there currently exists no authorised or satisfactory method of treatment, highlighting a vast area of unmet need, and yet the clinical development of orphan drugs is still fraught with many practical challenges.
5th December 2018
The escalating counterfeit problem in the pharmaceutical industry is causing damage to companies and putting lives at risk.
5th December 2018
The 2018 Access to Medicines Index is encouraging and shows that the pharmaceutical industry continues to do more to improve access to medicine in low- and middle-income countries.
3rd December 2018
Could innovation (true and urgent cross-sector partnership-led innovation) really be the key to tackling the world’s major global health pandemics?
28th November 2018
Second medical use patents have taken a blow with the Supreme Court’s recent ruling in Warner-Lambert v Mylan and Actavis.
21st November 2018
For pharmaceutical and life sciences firms, a case-by-case approach to information and content management has been prevalent for too long
13th November 2018
We spoke to Medidata’s General Manager and Senior Vice President EMEA Christian Hebenstreit at the New York NEXT conference to find out how virtual trials could change R&D
12th November 2018
London leads this increasingly important study by a huge margin, finds new study
26th October 2018
A review of the UK Bribery Act could mean pharma needs to adapt to changes in legislation
25th October 2018
How pharma companies are starting to lead the change in workplace mental health
10th October 2018
What the proposed changes to the National Institutes of Health Recombinant DNA Advisory Committee mean for patients and drug developers
9th October 2018
